How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD

References

• Li K, Liu H, Jiang Q. Overview and analysis on the national medical insurance negotiation drugs over the years: Taking anti-cancer drugs as an example. Anti-Tumor Pharmacy. 2021;11(2):229–235.
   Google Scholar
• Guan WJ, Zheng XY, Chung KF, et al. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. Lancet. 2016;388(10054):1939–1951.
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717.
   PubMed Web of Science ®Google Scholar
• Li J, Feng R, Cui Y, et al. Analysis on the affordability and economic risk for using medicine to treat patients with chronic obstructive pulmonary disease in tier 3 hospitals in China. Chinese Health Economics. 2015;34(9):66–68.
   Google Scholar
• Gold. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 report); 2021. Available from: https://goldcopd.org/2022-gold-reports-2/
   Google Scholar
• Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017;152(6):1169–1178.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357.
   PubMed Web of Science ®Google Scholar
• NHSA. National Healthcare Security Administration and Ministry of Human Resource and Social Security of the People′s Republic of China announced the national reimbursement drug list 2020; 2020. Available from: http://www.nhsa.gov.cn/art/2020/12/28/art_14_4221.html.
   Google Scholar
• Lipworth BJ, Collier DJ, Gon Y, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized phase III study conducted in Asia, Europe, and the USA. COPD. 2018;13:2969–2984.
   Google Scholar
• Hanania NA, Tashkin DP, Kerwin EM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–115.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377(10):923–935.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health. 2014;17(5):525–536.
   PubMed Web of Science ®Google Scholar
• Polański J, Chabowski M, Świątoniowska-Lonc N, et al. Medication compliance in COPD patients. Adv Exp Med Biol. 2020;1279:81–91.
   PubMed Web of Science ®Google Scholar
• Siddiqui MK, Shukla P, Jenkins M, et al. Systematic review and network Meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD. Ther Adv Respir Dis. 2019;13:1753466619894502.
   Web of Science ®Google Scholar
• Capel M, Mareque M, Álvarez CJ, et al. Cost-Effectiveness of Fixed-Dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig. 2018;38(7):611–620.
   PubMed Web of Science ®Google Scholar
• NHFPC. Report on Chinese residents′ chronic disease and nutrition. 1.0 edition. Beijing: People′s Medical Publishing House; 2017.
   Google Scholar
• Mu K, Liu S. Compilation of the normal values of the lung function. Beijing, China: Peking University Medical Press; 1990.
   Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Kotchie RW, Mork AC, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15(1):69–82.
   PubMed Web of Science ®Google Scholar
• Feng N, Cui H, Zhang Z, et al. Tabulation on the 2010 population census of the people′s republic of China. Beijing: China Statistics Press; 2012.
   Google Scholar
• Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res. 2005;6:98.
   PubMed Web of Science ®Google Scholar
• AECOPD-Panel. Chinese expert′s consensus on the treatment of AECOPD. Int J Respir. 2017;37(14):1041–1057.
   Google Scholar
• Jia G, Lu M, Wu R, et al. Gender difference on the knowledge, attitude, and practice of COPD diagnosis and treatment: a national, multicenter, cross-sectional survey in China. COPD. 2018;13:3269–3280.
   Google Scholar
• Zhang J, Zheng J, Huang K, et al. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12:1753466618769514.
   Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036.
   PubMed Web of Science ®Google Scholar
• MENET. Drug bidding database; 2021. Available from: https://www.menet.com.cn/.
   Google Scholar
• Di M, Cao Y, Huang H, et al. Investigation on the expenses of 248 adult patients with community-acquired pneumonia in Dongcheng district, Beijing. Modern Prevent Med. 2014;41(14):2560–2562.
   Google Scholar
• National BOS. Yearly price index; 2021 [accessed 2020 Aug 24]. Available from: https://data.stats.gov.cn/easyquery.htm?cn=C01.
   Google Scholar
• Liu GG. China guidelines for pharmacoeconomic evaluations. 1st edition. Beijing: China Market Press; 2020.
   Google Scholar
• Wu M, Zhao Q, Chen Y, et al. Quality of life and its association with direct medical costs for COPD in urban China. Health Qual Life Outcomes. 2015;13:57.
   PubMed Web of Science ®Google Scholar
• Rutten-Van MM, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465–477.
   PubMed Web of Science ®Google Scholar
• Mangen MJ, Huijts SM, Bonten MJ, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.
   PubMed Web of Science ®Google Scholar
• Jayasundara K, Hollis A, Krahn M, et al. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis. 2019;14(1):12.
   PubMed Web of Science ®Google Scholar
• Yuan S, Wu Y. The establishment of index system for the evaluation of health insurance coverage of orphan drugs in China. Chinese Health Resources. 2021;24(6):1–4.
   Google Scholar
• Guan X, Wang L, Li H. Cause analysis of “not cost-effective at a zero price” results in pharmacoeconomic evaluation. China Pharmacv. 2021;32(18):2242–2247.
   Google Scholar
• Hoogendoorn M, Corro RI, Soulard S, et al. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. BMJ Open. 2021;11(8):e049675.
   PubMed Web of Science ®Google Scholar
• Chan MC, Tan EC, Yang MC. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1079–1088.
   PubMed Web of Science ®Google Scholar
• Selya-Hammer C, Gonzalez-Rojas GN, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391–401.
   PubMed Web of Science ®Google Scholar